These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

962 related items for PubMed ID: 24457069

  • 21. Dual mTORC1/2 inhibition in a preclinical xenograft tumor model of endometrial cancer.
    Korets SB, Musa F, Curtin J, Blank SV, Schneider RJ.
    Gynecol Oncol; 2014 Feb; 132(2):468-73. PubMed ID: 24316308
    [Abstract] [Full Text] [Related]

  • 22. Heregulin controls ERα and HER2 signaling in mammospheres of ERα-positive breast cancer cells and interferes with the efficacy of molecular targeted therapy.
    Fukui F, Hayashi SI, Yamaguchi Y.
    J Steroid Biochem Mol Biol; 2020 Jul; 201():105698. PubMed ID: 32404282
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
    deGraffenried LA, Friedrichs WE, Russell DH, Donzis EJ, Middleton AK, Silva JM, Roth RA, Hidalgo M.
    Clin Cancer Res; 2004 Dec 01; 10(23):8059-67. PubMed ID: 15585641
    [Abstract] [Full Text] [Related]

  • 25. The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancer.
    Bean JR, Hosford SR, Symonds LK, Owens P, Dillon LM, Yang W, Shee K, Schwartz GN, Marotti JD, Muller KE, Rosenkranz KM, Barth RJ, Chen VS, Agarwal VR, Miller TW.
    Breast Cancer Res Treat; 2015 Jan 01; 149(1):69-79. PubMed ID: 25491778
    [Abstract] [Full Text] [Related]

  • 26. Effective combination therapies in preclinical endocrine resistant breast cancer models harboring ER mutations.
    Ladd B, Mazzola AM, Bihani T, Lai Z, Bradford J, Collins M, Barry E, Goeppert AU, Weir HM, Hearne K, Renshaw JG, Mohseni M, Hurt E, Jalla S, Bao H, Hollingsworth R, Reimer C, Zinda M, Fawell S, D'Cruz CM.
    Oncotarget; 2016 Aug 23; 7(34):54120-54136. PubMed ID: 27472462
    [Abstract] [Full Text] [Related]

  • 27. Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib.
    Serova M, de Gramont A, Tijeras-Raballand A, Dos Santos C, Riveiro ME, Slimane K, Faivre S, Raymond E.
    Cancer Chemother Pharmacol; 2013 May 23; 71(5):1297-307. PubMed ID: 23479136
    [Abstract] [Full Text] [Related]

  • 28. The mTOR inhibitor AZD8055 overcomes tamoxifen resistance in breast cancer cells by down-regulating HSPB8.
    Shi JJ, Chen SM, Guo CL, Li YX, Ding J, Meng LH.
    Acta Pharmacol Sin; 2018 Aug 23; 39(8):1338-1346. PubMed ID: 29345254
    [Abstract] [Full Text] [Related]

  • 29. Translational studies within the TAMRAD randomized GINECO trial: evidence for mTORC1 activation marker as a predictive factor for everolimus efficacy in advanced breast cancer.
    Treilleux I, Arnedos M, Cropet C, Wang Q, Ferrero JM, Abadie-Lacourtoisie S, Levy C, Legouffe E, Lortholary A, Pujade-Lauraine E, Bourcier AV, Eymard JC, Spaeth D, Bachelot T.
    Ann Oncol; 2015 Jan 23; 26(1):120-125. PubMed ID: 25361980
    [Abstract] [Full Text] [Related]

  • 30. Transferrin receptor (CD71) is a marker of poor prognosis in breast cancer and can predict response to tamoxifen.
    Habashy HO, Powe DG, Staka CM, Rakha EA, Ball G, Green AR, Aleskandarany M, Paish EC, Douglas Macmillan R, Nicholson RI, Ellis IO, Gee JM.
    Breast Cancer Res Treat; 2010 Jan 23; 119(2):283-93. PubMed ID: 19238537
    [Abstract] [Full Text] [Related]

  • 31. Adipocyte-conditioned medium induces tamoxifen resistance by activating PI3K/Akt/mTOR pathway in estrogen receptor-positive breast cancer cells.
    Nakatsuji M, Fujimori K.
    Biochim Biophys Acta Mol Cell Res; 2024 Oct 23; 1871(7):119821. PubMed ID: 39159684
    [Abstract] [Full Text] [Related]

  • 32. Comparison of the effects of the PI3K/mTOR inhibitors NVP-BEZ235 and GSK2126458 on tamoxifen-resistant breast cancer cells.
    Leung E, Kim JE, Rewcastle GW, Finlay GJ, Baguley BC.
    Cancer Biol Ther; 2011 Jun 01; 11(11):938-46. PubMed ID: 21464613
    [Abstract] [Full Text] [Related]

  • 33. Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistance.
    Morrison G, Fu X, Shea M, Nanda S, Giuliano M, Wang T, Klinowska T, Osborne CK, Rimawi MF, Schiff R.
    Breast Cancer Res Treat; 2014 Apr 01; 144(2):263-72. PubMed ID: 24554387
    [Abstract] [Full Text] [Related]

  • 34. Activating transcription factor-2 (ATF2) is a key determinant of resistance to endocrine treatment in an in vitro model of breast cancer.
    Giannoudis A, Malki MI, Rudraraju B, Mohhamed H, Menon S, Liloglou T, Ali S, Carroll JS, Palmieri C.
    Breast Cancer Res; 2020 Nov 16; 22(1):126. PubMed ID: 33198803
    [Abstract] [Full Text] [Related]

  • 35. Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications.
    Fourneaux B, Chaire V, Lucchesi C, Karanian M, Pineau R, Laroche-Clary A, Italiano A.
    Oncotarget; 2017 Jan 31; 8(5):7878-7890. PubMed ID: 28002802
    [Abstract] [Full Text] [Related]

  • 36. Dual inhibition of PI3K and mTOR signaling pathways decreases human pancreatic neuroendocrine tumor metastatic progression.
    Djukom C, Porro LJ, Mrazek A, Townsend CM, Hellmich MR, Chao C.
    Pancreas; 2014 Jan 31; 43(1):88-92. PubMed ID: 24263107
    [Abstract] [Full Text] [Related]

  • 37. Focal Adhesion- and IGF1R-Dependent Survival and Migratory Pathways Mediate Tumor Resistance to mTORC1/2 Inhibition.
    Yoon SO, Shin S, Karreth FA, Buel GR, Jedrychowski MP, Plas DR, Dedhar S, Gygi SP, Roux PP, Dephoure N, Blenis J.
    Mol Cell; 2017 Aug 03; 67(3):512-527.e4. PubMed ID: 28757207
    [Abstract] [Full Text] [Related]

  • 38. Decreased ER dependency after acquired resistance to CDK4/6 inhibitors.
    Iida M, Toyosawa D, Nakamura M, Tsuboi K, Tokuda E, Niwa T, Ishida T, Hayashi SI.
    Breast Cancer; 2020 Sep 03; 27(5):963-972. PubMed ID: 32297248
    [Abstract] [Full Text] [Related]

  • 39. Potent dual inhibitors of TORC1 and TORC2 complexes (KU-0063794 and KU-0068650) demonstrate in vitro and ex vivo anti-keloid scar activity.
    Syed F, Sanganee HJ, Singh S, Bahl A, Bayat A.
    J Invest Dermatol; 2013 May 03; 133(5):1340-50. PubMed ID: 23303455
    [Abstract] [Full Text] [Related]

  • 40. mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer.
    Elkabets M, Vora S, Juric D, Morse N, Mino-Kenudson M, Muranen T, Tao J, Campos AB, Rodon J, Ibrahim YH, Serra V, Rodrik-Outmezguine V, Hazra S, Singh S, Kim P, Quadt C, Liu M, Huang A, Rosen N, Engelman JA, Scaltriti M, Baselga J.
    Sci Transl Med; 2013 Jul 31; 5(196):196ra99. PubMed ID: 23903756
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 49.